N1 Single lymph node metastasis, 2 cm or less in greatest ... The subtypes investigated in bladder cancer were CK19, CK20 and CK7 IHC/RT-PCR CK20: 56–46% [98,99]; CK7: 100% [99]; CK1: 93.1% ...

for bladder cancer may improve outcomes. The research, published in the journal Urologic Oncology: Seminars and Original Investigations, focused on metastatic urothelial carcinoma (mUC), cancer ...

Extracellular DNA in patients with urothelial carcinoma of the bladder. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text ...

Though less common, it carries a higher risk of spreading to other areas of the body. When bladder cancer spreads to distant ...

The term nonmuscle invasive bladder cancer covers a spectrum of tumors ... aggressively and progress to muscle invasion and even metastatic disease. At present, the clinical behavior of T1 tumors ...

Evaluating the contribution of circulating tumor DNA (ctDNA) towards magnetic resonance imaging (MRI) in clinical staging and response assessment of patients with muscle-invasive bladder cancer (MIBC) ...

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...

Utilizing a query of the Indiana University bladder cancer database, investigators identified patients with locally advanced and metastatic bladder and upper tract urothelial carcinoma treated with ...

Opens in a new tab or window SAN FRANCISCO -- Neoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates of metastasis-free ...